Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hill A, Moyle G. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med 2007; 8: 259-264. Methodological accuracy in cross-trial comparisons of antiretroviral regimens in multitreated patients.
Llibre JM, Pérez-Alvarez N. Llibre JM, et al. HIV Med. 2007 Nov;8(8):568-70; author reply 571-2. doi: 10.1111/j.1468-1293.2007.00503.x. HIV Med. 2007. PMID: 17944691 Free article. No abstract available.
Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
Llibre JM, Bonjoch A, Iribarren J, Galindo MJ, Negredo E, Domingo P, Pérez-Alvarez N, Martinez-Picado J, Schapiro J, Clotet B; HIV Conference Call Study Group. Llibre JM, et al. HIV Med. 2008 Aug;9(7):508-13. doi: 10.1111/j.1468-1293.2008.00581.x. Epub 2008 May 15. HIV Med. 2008. PMID: 18484978 Free article.
Transient treatment exclusively containing nucleoside analogue reverse transcriptase inhibitors in highly antiretroviral-experienced patients preserves viral benefit when a fully active therapy was initiated.
Bonjoch A, Buzon MJ, Llibre JM, Negredo E, Puig J, Pérez-Alvarez N, Videla S, Martinez-Picado J, Clotet B. Bonjoch A, et al. HIV Clin Trials. 2008 Nov-Dec;9(6):387-98. doi: 10.1310/hct0906-387. HIV Clin Trials. 2008. PMID: 19203904 Clinical Trial.
Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients.
Bonjoch A, Paredes R, Domingo P, Cervantes M, Pedrol E, Ribera E, Force L, Llibre JM, Vilaró J, Dalmau D, Cucurull J, Mascaró J, Masabeu A, Pérez-Alvarez N, Puig J, Cinquegrana D, Clotet B. Bonjoch A, et al. AIDS Res Hum Retroviruses. 2006 Apr;22(4):321-9. doi: 10.1089/aid.2006.22.321. AIDS Res Hum Retroviruses. 2006. PMID: 16623634
Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.
Moltó J, Santos JR, Pérez-Alvarez N, Cedeño S, Miranda C, Khoo S, Else L, Llibre JM, Valle M, Clotet B. Moltó J, et al. Antimicrob Agents Chemother. 2008 Nov;52(11):3928-32. doi: 10.1128/AAC.00520-08. Epub 2008 Aug 25. Antimicrob Agents Chemother. 2008. PMID: 18725446 Free PMC article.
Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy.
Negredo E, Massanella M, Puertas MC, Buzón MJ, Puig J, Pérez-Alvárez N, Pérez-Santiago J, Bonjoch A, Moltó J, Jou A, Echeverría P, Llibre JM, Martínez-Picado J, Clotet B, Blanco J. Negredo E, et al. J Antimicrob Chemother. 2013 Oct;68(10):2358-62. doi: 10.1093/jac/dkt183. Epub 2013 May 14. J Antimicrob Chemother. 2013. PMID: 23677919 Free PMC article. Clinical Trial.
Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial.
Llibre JM, Alvarez H, Antela A, Toro J, Payeras A, Pérez-Elías MJ, Imaz A, Masià M, Pérez-Alvarez N, Burgos J, Clotet B; Members of the Nuke-Out Study. Llibre JM, et al. J Antimicrob Chemother. 2016 May;71(5):1346-51. doi: 10.1093/jac/dkv461. Epub 2016 Jan 23. J Antimicrob Chemother. 2016. PMID: 26803719 Clinical Trial.
89 results